Several biomarkers such as the expression of programmed cell death ligand 1 (PD-L1), tumor mutation burden (TMB), and microsatellite instability-high (MSI-H)/mismatch repair-deficiency (dMMR) have proven to be predictors for anti-tumor efficacy of ICIs (122, 123). This evidence concerns the gene CD274 and neoplasm.